trimetrexate has been researched along with Mucositis, Oral in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| "Trimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with methotrexate and has a wide spectrum of preclinical activity." | 1.28 | A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. ( Bishop, JF; Friedlander, ML; Morris, R; Olver, IN; Raghavan, D; Reece, P, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hudes, GR | 1 |
| LaCreta, F | 1 |
| DeLap, RJ | 1 |
| Grillo-Lopez, AJ | 1 |
| Catalano, R | 1 |
| Comis, RL | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Olver, IN | 1 |
| Reece, P | 1 |
| Morris, R | 1 |
| Friedlander, ML | 1 |
2 other studies available for trimetrexate and Mucositis, Oral
| Article | Year |
|---|---|
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; I | 1989 |